Blueprint Neurotherapeutics Network for Biologics (BPN Biologics)
Department of Health and Human Services ▸ National Institutes of Health ▸
Description
The Blueprint Neurotherapeutics Network for Biologics (BPN Biologics) program supports the discovery and development of biologics-based therapies, from lead optimization to early clinical trials. This is a collaborative agreement involving regular interaction with NIH staff. Funded projects get research funding and guidance from NIH-funded consultants with industry expertise. Participants can also collaborate with NIH-funded organizations for manufacturing and trials. Institutions keep their…
The Blueprint Neurotherapeutics Network for Biologics (BPN Biologics) program provides support for biologics-based therapy discovery and development activities from lead optimization through first-in-human clinical trials. This NOFO is a phased, milestone-driven cooperative agreement that involv…
Source
Grant ID
PAR-24-294
Funding Source
Department of Health and Human Services ▸ National Institutes of Health ▸
Program
SBIR
Key Dates
Opportunity Released
October 1, 2024
Open for Submission
October 1, 2024
Submission Deadline
August 18, 2027
Application Window Closes
August 18, 2027
Eligibility
The following categories of applicants are invited to apply:
- For-Profit Organizations: U.S. Small Business Concerns (SBCs) meeting SBA SBIR/STTR definition (organized for profit; U.S. place of business; operates primarily in the U.S. or contributes significantly to the U.S. economy; ≤500 employees including affiliates; ownership/control per SBA)
- SBIR-only: U.S. SBCs majority-owned by multiple venture capital operating companies, hedge funds, or private equity firms (no single such firm may own >50% unless it itself qualifies as an eligible SBC)
- Joint Ventures of eligible U.S. SBCs (each JV entity must independently meet SBA ownership/control requirements; JV must have <50% participation by foreign business entities; must comply with 13 CFR 121.705(b) registration/proposal requirements)
Similar opportunities
- Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics): Biologics-based Therapy Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
- Forecast for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional
- Notice of Funding Opportunity for Translational Efforts in Drug Discovery for Non-Opioid Pain Treatments
- Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
- Notice of Funding Opportunity Purpose